Health News Releases

  • Today November 13
Double Logo
April 22, 11:10
Rigaku Enters Strategic Alliance with Onto Innovation through 27 % Equity Investment
Rigaku Holdings Corporation (headquarters: Akishima, Tokyo; President and CEO: Jun Kawakami; “Rigaku”), a global leader in X-ray analytical technologies, today announced that it has entered into a str
PETG PharmaTainer™ bottles and carboys—RNase/DNase-free, ultra-clean, ready-to-use containers for bi
April 21, 15:30
Cleaner by Design: SaniSure Introduces PETG PharmaTainer™ Ultra-Clean Bottles & Carboys
SaniSure® today announced the launch of PETG PharmaTainer™, a new line of bioprocessing bottles and carboys combining widely accepted, medical-grade Eastman Eastar® PETG 6763 resin (DMF#9987) with San
April 21, 10:15
SBC Medical Announces Pricing of Secondary Public Offering of 3.1 Million Shares of Common Stock
SBC Medical Group Holdings Incorporated (Nasdaq: SBC) (“the Company”), a Management Service Organization operating a wide range of franchise businesses across diverse medical fields, today announced t
Electron microscope image of BK virus, showing the VP1 capsid protein that creates an icosahedral sh
April 20, 09:35
Orthogon Therapeutics Raises an Additional $11M Financing for Its BK Virus Antiviral Drug Program
Orthogon Therapeutics today announced the closing of a follow-on $11 million financing, bringing its total capital raised to $36 million. This financing supports the continued advancement of its first
April 19, 14:55
Byondis to Present Data from its Novel ADC Technology Platforms at the American Society for Cancer Research Meeting 2026
Byondis B.V., an independent biopharmaceutical company creating innovative targeted medicines for patients with cancer, will profile the Company’s first-in-class antifolate and phosphonate antibody-dr
Figure 1: Pincushion plant (Diapensia lapponica) in bloom, growing in alpine rocky areas. Its distri
April 17, 15:30
New Method Enables Structural Determination of Diverse Phenolic Compounds from a Tiny Alpine Flower Sample
Hyuga Hirano (United Graduate School of Agricultural Science, Tokyo University of Agriculture and Technology, and collaborative graduate student at the National Museum of Nature and Science (President
April 16, 15:30
Invivoscribe Announces the PrepQuant™ System, an Integrated Sample Preparation Platform that Standardizes and Streamlines Pre-Analytical Workflows
Invivoscribe®, a global leader in precision diagnostics and measurable residual disease (MRD) testing, today announced the launch of the PrepQuant™ System, a novel sample preparation platform that int
April 16, 14:19
Ferring Pharmaceuticals and Gallup Announce Landmark Global Public Attitudes Study on Fertility and Family-Building
Ferring Pharmaceuticals and Gallup today announced the Ferring Global Fertility Monitor, a global study on the factors influencing people’s fertility choices, at the 2026 Annual Convening of Semafor W
April 16, 14:12
Galderma Launches New Alastin Regenerating Skin Nectar with TriHex+™, Powered by Its Next-Generation TriHex Technology® Regenerative Platform
Galderma (SIX: GALD), the pure-play dermatology category leader, today announced the launch of Regenerating Skin Nectar with TriHex+™, the newest innovation from Alastin, a leader in peptide-based reg
April 15, 08:40
Samsung Bioepis Initiates Phase 1 Clinical Trial for SBE303, Nectin-4 Targeting Antibody-Drug Conjugate (ADC) Candidate
Samsung Bioepis Co., Ltd. announced today the initiation of Phase 1 clinical trial for SBE303. SBE303 is Samsung Bioepis’s first novel antibody-drug conjugate (ADC) candidate engineered to bind to Nec
IFF showcases wellness innovation for beauty.
April 14, 10:00
IFF Explores the Science Behind Well-Being at In‑Cosmetics Global 2026
IFF (NYSE: IFF)—a global leader in flavors, fragrances, food ingredients and health & biosciences—will showcase scent and bioscience innovations focused on wellness and sustainability at In‑Cosmetics
Clean Cells and Naobios Showcase Complete End-to-End Viral Vaccines and Vector Solutions at Bio Kore
April 13, 11:00
Clean Cells and Naobios Showcase Complete End-to-End Viral Vaccines and Vector Solutions at Bio Korea 2026
Clean Cells (https://clean-cells.com/), a leading biopharmaceutical quality control services provider specializing in biologics GMP testing, and Naobios (https://www.naobios.com/), a CDMO (Contract De
April 10, 15:35
Byondis Appoints Christoph Korpus, PhD, MBA as Chief Executive Officer
Byondis B.V., an independent biopharmaceutical company creating innovative targeted medicines for patients with cancer, announces today the appointment of Christoph Korpus, PhD, MBA, as Chief Executiv
April 09, 14:40
Interim Data From Two Ongoing Investigator-initiated Trials Highlight the Role of Sculptra® and Restylane® in Addressing Aesthetic Changes Associated With Weight Loss Medications and Menopause
Galderma (SIX: GALD), the pure-play dermatology category leader, today welcomes new data from two IITs, demonstrating the power of Sculptra - the first proven regenerative biostimulator - and the comp
April 08, 15:30
Variational AI Releases Enki 4: Major Update to Foundation Model for Small-Molecule Drug Discovery
Variational AI today announced the release of Enki™ 4, a major update to its generative AI platform for small-molecule drug discovery. The release of the fourth generation of Enki™ delivers significan
April 03, 13:30
VDYNE Receives FDA Approval to Initiate the TRIVITA[1] IDE Pivotal Trial of Transcatheter Tricuspid Valve Replacement System
VDYNE, Inc. (“VDYNE” or “the Company”), a privately held medical device company developing next generation transcatheter valve replacement technologies, today announced that the U.S. Food & Drug Admin
April 03, 11:30
Agenus Announces First Patient Enrolled in Global Phase 3 BATTMAN Trial of BOT+BAL Immunotherapy Combination in MSS or pMMR Metastatic Colorectal Cancer
Agenus (https://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.agenusbio.com&esheet=54475511&newsitemid=20260401039214&lan=en-US&anchor=Agenus&index=1&md5=543f2b7e0242fee88c23d833e5fff50
April 02, 14:30
Biocytogen and Sihuan Pharmaceutical Announce Strategic Partnership in Weight Loss and Beyond
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innova
WHOOP Raises $575 Million at $10.1 Billion Valuation to Advance Global Health Platform
April 02, 10:10
WHOOP Raises $575 Million at $10.1 Billion Valuation to Advance Global Health Platform
WHOOP (https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.whoop.com%2Fus%2Fen%2F&esheet=54472286&newsitemid=20260331399622&lan=en-US&anchor=WHOOP%2C&index=1&md5=5b3c0a4ec1e7066bef07
HistoSonics Non-Invasive Edison Histotripsy System. Image credit: HistoSonics
March 31, 09:50
HistoSonics Treats First Patients Evaluating the Edison® Histotripsy System for the Treatment of Benign Prostatic Hyperplasia (BPH)
HistoSonics (https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fhistosonics.com%2F&esheet=54465795&newsitemid=20260330349844&lan=en-US&anchor=HistoSonics&index=1&md5=83f0539aafc562f523a
March 31, 09:30
Biocytogen Grants Taisho Pharmaceutical a License to its RenNano® Fully Human Heavy Chain-Only Antibody Discovery Platform
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innova
March 30, 09:30
Angelalign Technology (6699.HK) Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global an
March 29, 11:45
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care
Takeda (TSE:4502/NYSE:TAK) today announced new data from the two pivotal Phase 3 studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adult
March 29, 11:25
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis
Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clin
March 29, 10:25
Biocytogen Announces FDA IND Clearance for Partner NEOK Bio’s NEOK002 Targeting Solid Tumors
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innova
25 per page50 per page75 per page100 per page